Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in italy. data from the DA-COVID-19 registry / Chiricozzi, A.; Talamonti, M.; De Simone, C.; Galluzzo, M.; Gori, N.; Fabbrocini, G.; Marzano, A. V.; Girolomoni, G.; Offidani, A.; Rossi, M. T.; Bianchi, L.; Cristaudo, A.; Fierro, M. T.; Stingeni, L.; Pellacani, G.; Argenziano, G.; Patrizi, A.; Pigatto, P.; Romanelli, M.; Savoia, P.; Rubegni, P.; Foti, C.; Milanesi, N.; Belloni Fortina, A.; Bongiorno, M. R.; Grieco, T.; Di Nuzzo, S.; Fargnoli, M. C.; Carugno, A.; Motolese, A.; Rongioletti, F.; Amerio, P.; Balestri, R.; Potenza, C.; Micali, G.; Patruno, C.; Zalaudek, I.; Lombardo, M.; Feliciani, C.; Di Nardo, L.; Guarneri, F.; Peris, K.; Caldarola, G.; Silvaggio, D.; Dattola, A.; Napolitano, M.; Ferrucci, S. M.; Dal Bello, G.; Bianchelli, T.; Rovati, C.; Pigliacelli, F.; Ortoncelli, M.; Hansel, K.; Calabrese, G.; Loi, C.; Iannone, M.; Veronese, F.; Romita, P.; Tronconi, G.; Caroppo, F.; Tilotta, G.; Sernicola, A.; Esposito, M.; Raponi, F.; Gualdi, G.; Rech, G.; Musumeci, M. L.; Nistico, S. P.; Campitiello, A.; Bonzano, L.; Piras, V.. - In: ALLERGY. - ISSN 0105-4538. - 76:6(2021), pp. 1813-1824. [10.1111/all.14767]
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in italy. data from the DA-COVID-19 registry
Chiricozzi A.;Talamonti M.;Rossi M. T.;Pellacani G.;Grieco T.;Potenza C.;Patruno C.;Guarneri F.;Silvaggio D.;Sernicola A.;Raponi F.;Campitiello A.;
2021
Abstract
Background: Few and small studies have described the management of immunomodulant/immunosuppressive therapies or phototherapy in atopic dermatitis (AD) patients during coronavirus disease 2019 (COVID-19) pandemic. Methods: A national registry, named DA-COVID-19 and involving 35 Italian dermatology units, was established in order to evaluate the impact of COVID-19 pandemic on the management of adult AD patients treated with systemic immunomodulant/immunosuppressive medications or phototherapy. Demographic and clinical data were obtained at different timepoints by teledermatology during COVID-19 pandemic, when regular visits were not allowed due to sanitary restrictions. Disease severity was assessed by both physician- and patient-reported assessment scores evaluating itch intensity, sleep disturbances, and AD severity. Results: A total of 1831 patients were included, with 1580/1831 (86.3%) continuing therapy during pandemic. Most patients were treated with dupilumab (86.1%, 1576/1831) that was interrupted in only 9.9% (156/1576) of cases, while systemic immunosuppressive compounds were more frequently withdrawn. Treatment interruption was due to decision of the patient, general practitioner, or dermatologist in 39.9% (114/286), 5.6% (16/286), and 30.1% (86/286) of cases, respectively. Fear of increased susceptibility to SARS-CoV-2 infection (24.8%, 71/286) was one of the main causes of interruption. Sixteen patients (0.9%) resulted positive to SARS-CoV-2 infection; 3 of them (0.2%) were hospitalized but no cases of COVID-related death occurred. Conclusions: Most AD patients continued systemic treatments during COVID pandemic and lockdown period, without high impact on disease control, particularly dupilumab-treated patients.| File | Dimensione | Formato | |
|---|---|---|---|
|
Chiricozzi_Management_2021.pdf
solo gestori archivio
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Tutti i diritti riservati (All rights reserved)
Dimensione
611.7 kB
Formato
Unknown
|
611.7 kB | Unknown | Contatta l'autore |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
